DeepMed Research

Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Phase 3

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2002-10-02

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 250

Registration Number: NCT00046501

Locations: 🇺🇸
Aventis, Bridgewater, New Jersey, United States

12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.

Phase 3

Completed

Conditions: Diabetes, Type I

First Posted Date: 2002-09-23

Last Posted Date: 2008-06-19

Lead Sponsor: Sanofi

Target Recruit Count: 59

Registration Number: NCT00046150

Locations: 🇳🇱
Sanofi-aventis Administrative Office, Gouda, Netherlands
🇫🇷
Hospital de Rangueil, Toulouse, France

Long-Term Safety Performance of Fexofenadine in Asthma

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2002-09-19

Last Posted Date: 2008-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 1200

Registration Number: NCT00045955

Locations: 🇺🇸
Aventis Pharmaceutical Inc., Bridgewater, New Jersey, United States

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2002-09-17

Last Posted Date: 2008-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 1000

Registration Number: NCT00044824

Locations: 🇲🇽
Sanofi-Aventis Administrative Office, Mexico, Mexico
🇨🇷
Sanofi-Aventis Admnistrative Office, Costa Rica, Costa Rica
🇭🇺
sanofi-aventis Hungaria, Budapest, Hungary

and more 3 locations

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2002-09-17

Last Posted Date: 2008-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 1000

Registration Number: NCT00044811

Locations: 🇺🇸
Aventis Pharmaceuticals Inc., Bridgewater, New Jersey, United States
🇨🇷
Sanofi-Aventis Admnistrative Office, Costa Rica, Costa Rica
🇷🇺
Sanofi-Aventis Administrative Office, Moscow, Russian Federation

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

Phase 3

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

First Posted Date: 2002-08-30

Last Posted Date: 2008-06-19

Lead Sponsor: Sanofi

Target Recruit Count: 170

Registration Number: NCT00044447

Locations: 🇺🇸
Dallas Diabetes & Endocrine Center, Dallas, Texas, United States

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

Phase 3

Completed

Conditions: Unstable Angina
Myocardial Infarction
Myocardial Ischemia

First Posted Date: 2002-08-15

Last Posted Date: 2008-09-16

Lead Sponsor: Sanofi

Target Recruit Count: 8000

Registration Number: NCT00043784

Locations: 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States

Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Phase 2

Completed

Conditions: Syndrome of Inappropriate ADH (SIADH) Secretion
Hyponatremia

First Posted Date: 2002-04-01

Last Posted Date: 2008-06-17

Lead Sponsor: Sanofi

Target Recruit Count: 35

Registration Number: NCT00032734

Locations: 🇭🇺
Sanofi-aventis Administrative Office, Budapest, Hungary

Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).

Phase 2

Completed

Conditions: Chronic Heart Failure

First Posted Date: 2002-04-01

Last Posted Date: 2008-06-17

Lead Sponsor: Sanofi

Target Recruit Count: 338

Registration Number: NCT00032747

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
MUSC/Division Cardiology, Charleston, South Carolina, United States
🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States

and more 5 locations

Obese Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Obesity
Diabetes Mellitus, Non-Insulin-Dependent
Obesity in Diabetes

First Posted Date: 2002-01-24

Last Posted Date: 2009-04-20

Lead Sponsor: Sanofi

Target Recruit Count: 1045

Registration Number: NCT00029848

Locations: 🇺🇸
The Chase Wellness Center, Inc., Virginia Beach, Virginia, United States
🇺🇸
Salem Veterans Affairs Medical Center (151), Salem, Virginia, United States
🇺🇸
Kansas University Medical Center, Kansas City, Kansas, United States

and more 40 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy